Nama's AI scorecard currently rates Zenas BioPharma Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ZBIO report earnings?

Zenas BioPharma's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$1.27.

What is the ZBIO price target?

The median analyst price target from 8 analysts is $46.50, with a range of $32.00 – $59.00.

Is ZBIO Shariah compliant?

Nama's AAOIFI-style screen reads Zenas BioPharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Zenas BioPharma (ZBIO)

Healthcare · Biotechnology · NASDAQ

Zenas BioPharma (ZBIO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.84B and a free-cash-flow yield of -16.4%. Over the most recent reported fiscal year, revenue grew 100.0%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 2.2/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -13.2% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-36.6%

How far the last close sits under the highest price of the past five years.

Market cap	$1.84B
Trailing P/E	—
Price / book	7.2
Price / sales	1413.0
FCF yield	-16.4%
Dividend yield	—
Gross margin	0.0%
Operating margin	-7765.9%
Net margin	0.0%
Revenue growth (YoY)	+100.0%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	-0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ZBIO earnings

Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$1.27). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 13, 2026	-$1.77	-$0.75	-136.0%	$1.00M
Q1 2026	May 13, 2026	-$1.46	-$1.54	+5.2%	$0
Q4 2025	Mar 16, 2026	-$1.39	-$1.19	-16.8%	$0
Q3 2025	Nov 12, 2025	-$1.22	-$0.85	-43.5%	$0

ZBIO analyst price target

Median target $46.50 from 8 analysts, ranging $32.00 – $59.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ZBIO data on Nama Insights →

ZBIO FAQ

Is ZBIO a buy?: Nama's AI scorecard currently rates Zenas BioPharma Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ZBIO report earnings?: Zenas BioPharma's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$1.27.
What is the ZBIO price target?: The median analyst price target from 8 analysts is $46.50, with a range of $32.00 – $59.00.
Is ZBIO Shariah compliant?: Nama's AAOIFI-style screen reads Zenas BioPharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.